ATE437367T1 - Detektion und diagnose von übertragbaren spongiformen enzephalopathien - Google Patents
Detektion und diagnose von übertragbaren spongiformen enzephalopathienInfo
- Publication number
- ATE437367T1 ATE437367T1 AT03257981T AT03257981T ATE437367T1 AT E437367 T1 ATE437367 T1 AT E437367T1 AT 03257981 T AT03257981 T AT 03257981T AT 03257981 T AT03257981 T AT 03257981T AT E437367 T1 ATE437367 T1 AT E437367T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnosis
- detection
- spongiform encephalopathies
- transmissable spongiform
- transmissable
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2872—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/968—Plasmin, i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43462702P | 2002-12-19 | 2002-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437367T1 true ATE437367T1 (de) | 2009-08-15 |
Family
ID=32508037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03257981T ATE437367T1 (de) | 2002-12-19 | 2003-12-18 | Detektion und diagnose von übertragbaren spongiformen enzephalopathien |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1435521B1 (de) |
| JP (1) | JP4444644B2 (de) |
| AT (1) | ATE437367T1 (de) |
| AU (1) | AU2003266801B2 (de) |
| CA (1) | CA2452946C (de) |
| DE (1) | DE60328450D1 (de) |
| ES (1) | ES2328027T3 (de) |
| PT (1) | PT1435521E (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445615A1 (de) * | 2003-02-10 | 2004-08-11 | Ortho-Clinical Diagnostics, Inc. | Methode zur unterscheidung zwischen infektiösen und nicht-infektiösen prionen |
| EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
| AU2005209592B2 (en) * | 2004-09-30 | 2012-07-12 | Ortho-Clinical Diagnostics, Inc. | Peptides for discrimination of prions |
| US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
| US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
| DK2514823T3 (en) | 2006-03-03 | 2018-07-23 | Promis Neurosciences Inc | Methods and compositions for treating and detecting failed SOD1-mediated diseases |
| FR2973114A1 (fr) * | 2011-03-21 | 2012-09-28 | Ets Francais Du Sang | Nanobilles recouvertes de plasminogene comme support direct d'amplification cyclique de la proteine prion prpsc |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806627A (en) * | 1987-05-29 | 1989-02-21 | Research Foundation Of Mental Hygiene Inc. | Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins |
| EP0910408A4 (de) * | 1996-03-08 | 2004-01-14 | Univ California | Darreichungssystem mit mab 3e10, mutanten und/oder funktionalen fragmenten davon |
| EP0861900A1 (de) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunologischer Nachweis von Prionen |
-
2003
- 2003-12-09 AU AU2003266801A patent/AU2003266801B2/en not_active Ceased
- 2003-12-12 CA CA2452946A patent/CA2452946C/en not_active Expired - Fee Related
- 2003-12-18 ES ES03257981T patent/ES2328027T3/es not_active Expired - Lifetime
- 2003-12-18 PT PT03257981T patent/PT1435521E/pt unknown
- 2003-12-18 AT AT03257981T patent/ATE437367T1/de active
- 2003-12-18 DE DE60328450T patent/DE60328450D1/de not_active Expired - Lifetime
- 2003-12-18 EP EP03257981A patent/EP1435521B1/de not_active Expired - Lifetime
- 2003-12-19 JP JP2003422015A patent/JP4444644B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003266801A1 (en) | 2004-07-08 |
| ES2328027T3 (es) | 2009-11-06 |
| JP2004198432A (ja) | 2004-07-15 |
| CA2452946A1 (en) | 2004-06-19 |
| PT1435521E (pt) | 2009-08-27 |
| CA2452946C (en) | 2014-02-11 |
| EP1435521A1 (de) | 2004-07-07 |
| DE60328450D1 (de) | 2009-09-03 |
| EP1435521B1 (de) | 2009-07-22 |
| AU2003266801B2 (en) | 2010-02-25 |
| JP4444644B2 (ja) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110188T1 (el) | Αντισωματα κατα συζυγων φωσφορυλχολινης | |
| CY1110606T1 (el) | Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου | |
| NL301089I2 (nl) | imlifidase | |
| CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| DE60239931D1 (de) | Kombinationstherapie | |
| DE602004029034D1 (de) | Replikin-peptide und anwendungen | |
| DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
| CY1105266T1 (el) | Αποστειρωση γλυκοκορτικοστepοειδων εναιωρηματων | |
| WO2004044204A3 (fr) | Fragments variables d'anticorps de camelides a chaine unique et leurs applications pour le diagnostic et le traitement de pathologies diverses. | |
| DK2075007T3 (da) | Behandling af Alzheimers sygdom | |
| CY1110721T1 (el) | Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις | |
| DE602004023201D1 (de) | Antimikrobielle medizinprodukte | |
| ES2179324T3 (es) | Un metodo de deteccion de las encefalopatias espongiformes transmisibles. | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| WO2003049717A3 (en) | Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases | |
| CY1114614T1 (el) | Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα | |
| DE60328450D1 (de) | Detektion und Diagnose von Übertragbaren Spongiformen Enzephalopathien | |
| NO20051521D0 (no) | Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt | |
| BR0010007A (pt) | Indicadores biológicos para validação de um processo de esterilização de prìon | |
| WO2005012330A3 (en) | AMYLOID β-PEPTIDE AND METHODS OF USE | |
| EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
| DE60335610D1 (de) | Neoplasma-spezifische antikörper und deren verwendungen | |
| ATE495269T1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
| PL1756581T3 (pl) | Sposób wykrywania prionu związanego z chorobą | |
| EP1614428A4 (de) | Arzneimittel zur vorbeugung oder behandlung angiogener augenerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1435521 Country of ref document: EP |
|
| UEP | Publication of translation of european patent specification |
Ref document number: 1435521 Country of ref document: EP |